Korolenko Tatyana, Johnston Thomas P, Lykov Alexander P, Shintyapina Alexandra B, Khrapova Marina V, Goncharova Natalya V, Korolenko Erik, Bgatova Nataliya P, Machova Eva, Nescakova Zuzana, Sakhno Ludmila V
Scientific Research Institute of Physiology and Basic Medicine, Novosibirsk, Russia.
Division of Pharmaceutical Sciences, University of Missouri-Kansas City, Kansas City, MO, USA.
J Pharm Pharmacol. 2016 Dec;68(12):1516-1526. doi: 10.1111/jphp.12633. Epub 2016 Oct 5.
We evaluated the hypolipidaemic effect of mannan Candida albicans serotype A, relative to atorvastatin, in a mouse model of hyperlipidaemia.
Mannan serotype A was investigated in vitro and in vivo to determine its effects on macrophage proliferation, nitric oxide (NO) production by cultured macrophages, serum and liver lipids, changes in liver morphology and serum chitotriosidase activity and its expression in the liver.
Mannan serotype A stimulates the macrophage proliferation and NO production in murine peritoneal macrophages in vitro. The activity of serum chitotriosidase (an enzyme released from the activated macrophages) was found to be significantly increased in P-407-induced hyperlipidaemic mice pretreated with low-dose mannan compared with mice administered P-407 only. Mannan treatment in mice was shown to significantly increase the chitotriosidase expression in the liver of both non-hyperlipidaemic and P-407-induced hyperlipidaemic mice. Lastly, mice pretreated with mannan before the induction of hyperlipidaemia with P-407 showed a significant reduction in the serum concentration of atherogenic LDL cholesterol, total cholesterol, triglycerides and liver triglycerides.
It is suggested that mannan serotype A, like β-glucan, may represent another hypolipidaemic agent, which could potentially be used as an adjunctive therapy with conventional antihyperlipidaemic drugs (statins and fibrates) in humans.
